MACROGENICS, INC. Increase (Decrease) in Contract with Customer, Liability
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Contract with Customer, Liability of -$2.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-14
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$4.30M.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $1.57M.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $282.00K.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $2.52M.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$5.40M.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$9.41M, a 182.39% decline from fiscal 2023.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $11.43M, a 76.60% decline from fiscal 2022.
- MACROGENICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $48.82M, a 427.00% increase from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.73M 10-Q · filed 2026-08-14 | -$2.45M derived: sum of 3 quarters · filed 2026-08-14 | $77.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-13 | $1.85M derived: sum of 2 quarters · filed 2026-05-13 | $4.38M derived: sum of 3 quarters · filed 2026-05-13 | -$3.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.81M derived: sum of 2 quarters · filed 2026-03-09 | -$5.13M derived: sum of 3 quarters · filed 2026-08-14 | -$5.40M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.42M derived: sum of 2 quarters · filed 2026-08-14 | -$5.68M 10-Q · filed 2025-11-12 | -$13.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$7.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.21M 10-Q · filed 2026-08-14 | -$15.54M derived: sum of 3 quarters · filed 2026-08-14 | -$16.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$264.00K 10-Q · filed 2026-05-13 | -$7.59M derived: sum of 2 quarters · filed 2026-05-13 | -$8.11M derived: sum of 3 quarters · filed 2026-05-13 | -$7.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$7.84M derived: sum of 2 quarters · filed 2026-03-09 | -$7.54M derived: sum of 3 quarters · filed 2026-03-09 | -$9.41M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$511.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$209.00K derived: sum of 2 quarters · filed 2025-11-12 | -$2.08M 10-Q · filed 2025-11-12 | -$4.03M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.57M 10-Q · filed 2025-08-14 | -$3.52M derived: sum of 3 quarters · filed 2026-03-09 | $11.11M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$1.88M 10-Q · filed 2025-05-13 | -$3.83M derived: sum of 2 quarters · filed 2026-03-09 | $10.81M derived: sum of 3 quarters · filed 2026-03-09 | $11.76M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.69M derived: sum of 2 quarters · filed 2026-03-09 | $13.64M derived: sum of 3 quarters · filed 2026-03-09 | $11.43M 10-K · filed 2026-03-09 |
| 2023-09-30 | $14.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $15.59M derived: sum of 2 quarters · filed 2024-11-05 | $13.38M 10-Q · filed 2024-11-05 | $70.67M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.26M 10-Q · filed 2024-08-06 | $56.04M derived: sum of 3 quarters · filed 2025-03-20 | $50.48M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | -$2.21M 10-Q · filed 2024-05-09 | $55.09M derived: sum of 2 quarters · filed 2025-03-20 | $49.53M derived: sum of 3 quarters · filed 2025-03-20 | $35.33M derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | $57.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $51.74M derived: sum of 2 quarters · filed 2025-03-20 | $37.54M derived: sum of 3 quarters · filed 2025-03-20 | $48.82M 10-K · filed 2025-03-20 |
| 2022-09-30 | -$5.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$19.76M derived: sum of 2 quarters · filed 2023-11-06 | -$8.48M 10-Q · filed 2023-11-06 | -$13.72M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$14.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.92M 10-Q · filed 2023-08-09 | -$8.16M derived: sum of 3 quarters · filed 2024-03-07 | -$12.31M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $11.28M 10-Q · filed 2023-05-09 | $6.04M derived: sum of 2 quarters · filed 2024-03-07 | $1.89M derived: sum of 3 quarters · filed 2024-03-07 | $21.14M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$9.39M derived: sum of 2 quarters · filed 2024-03-07 | $9.87M derived: sum of 3 quarters · filed 2024-03-07 | $9.26M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$4.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $15.11M derived: sum of 2 quarters · filed 2022-11-03 | $14.51M 10-Q · filed 2022-11-03 | $10.85M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $19.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $18.66M 10-Q · filed 2022-08-08 | $15.00M derived: sum of 3 quarters · filed 2023-03-15 | $13.95M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$601.00K 10-Q · filed 2022-05-03 | -$4.26M derived: sum of 2 quarters · filed 2023-03-15 | -$5.31M derived: sum of 3 quarters · filed 2023-03-15 | -$6.83M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$4.71M derived: sum of 2 quarters · filed 2023-03-15 | -$6.22M derived: sum of 3 quarters · filed 2023-03-15 | -$8.47M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$2.57M derived: sum of 2 quarters · filed 2021-11-02 | -$4.82M 10-Q · filed 2021-11-02 | -$18.57M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$3.77M 10-Q · filed 2021-07-29 | -$17.52M derived: sum of 3 quarters · filed 2022-02-24 | -$13.78M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$2.25M 10-Q · filed 2021-04-29 | -$16.00M derived: sum of 2 quarters · filed 2022-02-24 | -$12.26M derived: sum of 3 quarters · filed 2022-02-24 | -$17.69M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$13.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$10.01M derived: sum of 2 quarters · filed 2022-02-24 | -$15.44M derived: sum of 3 quarters · filed 2022-02-24 | -$20.87M 10-K · filed 2022-02-24 |
| 2019-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$1.68M derived: sum of 2 quarters · filed 2020-11-04 | -$7.11M 10-Q · filed 2020-11-04 | $12.10M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | -$10.86M 10-Q · filed 2020-07-31 | $8.35M derived: sum of 3 quarters · filed 2021-02-25 | $5.92M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$5.43M 10-Q · filed 2020-05-05 | $13.78M derived: sum of 2 quarters · filed 2021-02-25 | $11.35M derived: sum of 3 quarters · filed 2021-02-25 | $9.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $19.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $16.78M derived: sum of 2 quarters · filed 2021-02-25 | $14.84M derived: sum of 3 quarters · filed 2021-02-25 | $13.40M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$4.37M derived: sum of 2 quarters · filed 2019-11-06 | -$5.81M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$3.37M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | -$1.44M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $6.53M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |